Context
Over the past decade, the introduction of generic versions of newer antidepressants and the release of FDA-warnings regarding suicidality in children, adolescents, and young adults may have had an impact on cost and quality of depression treatment.
Objectives
To examine longitudinal trends in service use, spending, and treatment quality for depression.
Design
Observational, trend study.
Setting
Florida, Medicaid enrollees from July 1996 to June 2006.
Subjects
Annual cohorts aged 18-64 diagnosed with depression.
Main Outcome Measures
Mental-health spending adjusted for inflation and case mix and components of mental-health spending, including inpatient, outpatient, and medication expenditures. Quality measures included measures of medication adherence, psychotherapy, and follow-up visits.
Results
Mental-health spending increased from an average of $2802 per enrollee to $3610 over this time period (29% increase). This increase occurred despite a mean decrease in inpatient spending (from $641 per enrollee to $373) and was driven primarily by an increase in pharmaceutical spending (up 110%) the bulk of which was due to spending on antipsychotics (up 949%). The percentage of enrollees with depression who were hospitalized decreased from 57% to 37% and the percentage using psychotherapy decreased from 9% to 5%. Antidepressant use increased from 82% to 87%, anxiety medication use was unchanged at 64%, and antipsychotic use increased from 27% to 42%. Changes in treatment quality were mixed, with measures of antidepressant use improving slightly, measures examining follow-up visits decreasing, and measures of psychotherapy utilization fluctuating.
Conclusions
Over a ten-year period, we found a substantial increase in spending for enrollees with depression associated with minimal improvements in quality of care. Antipsychotic use contributed significantly to the increase in spending while contributing little to traditional measures of quality.